• No image available for this medication
    • ALLERGY NASAL MIST

    • QTY 15
    • 0.05 %
    • MIST
    • Near  77381

OXYMETAZOLINE (OX ee me TAZ oh leen) treats a runny or stuffy nose. It may also be used to treat sinus congestion and pressure. It is often used for a short period of time. It works by decreasing swelling in the nose, making it easier to breathe. It belongs to a group of medications called decongestants.


ALLERGY NASAL MIST Lifestyle Interactions

  • Ranolazine 500mg, Oral tablet, extended release

    Interaction: Alcohol
    Severity: Major
    Notes for Consumers: Some forms of this medication may have other interactions. Discuss the form you are taking with your care team. Drinking alcohol may alter the effects of your medication. Serious side effects may occur. Contact your care team if you experience new or worsening side effects.
    Notes for Professionals: Advise patients taking ranolazine extended-release oral granules to avoid alcohol ingestion; alcohol may cause a rapid-release of medication that can cause serious side effects, including QT prolongation.
  • Ranolazine 500mg, Oral tablet, extended release

    Interaction: Grapefruit juice
    Severity: Major
    Notes for Consumers: Avoid grapefruit and grapefruit juice when taking this medication. Discuss this combination with your care team before taking grapefruit and Ranolazine together. They may recommend changes to your treatment plan to lower the risk of side effects. A dangerous change in heartbeat or rhythm may occur. Call emergency services right away if you experience chest pain, heart palpitations, shortness of breath, dizziness, fainting, or a fast or irregular heartbeat.
    Notes for Professionals: Patients should limit intake of grapefruit juice during ranolazine treatment and avoid grapefruit-containing products and grapefruit juice if possible. If ingestion of grapefruit juice is not avoidable, limit the dose of ranolazine to 500 mg PO twice daily. Grapefruit juice is a CYP3A inhibitor. Ranolazine is a CYP3A4 and P-gp substrate; coadministration is expected to increase ranolazine plasma concentrations/exposure and may increase the risk for side effects, such as QT prolongation.

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.